Connect Sign In
CEBPA Mutation Detection
Ordering Recommendation
Initial test for prognostication of CN-AML.
Methodology
Polymerase Chain Reaction/Sequencing
Performed
Mon, Wed, Fri
Reported
7-14 days
New York DOH Approval Status
Specimen Required
Lavender (EDTA) or bone marrow (EDTA).
Whole Blood: Do not freeze. Transport 5 mL whole blood (Min: 1 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)
Refrigerated.
Plasma, serum, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
Reference Interval
Interpretive Data
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
CPT Codes
81218
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2004249 | CEBPA Mutation Detection Results | 64012-8 |
Aliases
- CCAAT Enhancer Binding Protein Alpha
- CEBP Alpha
- CEBPA Mutation Analysis
Feedback
